Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?

Journal of the American College of Cardiology

Volumn 29, Issue 6, 1997, Pages 1206-1213

  Slatton, Monte L ^a   Irani, Waleed N ^a   Hall, Shelley A ^a   Marcoux, Lucille G ^a   Page, Richard L ^a   Grayburn, Paul A ^a   Eichhorn, Eric J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; NITROPRUSSIDE SODIUM;

ADULT; AGED; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ECHOCARDIOGRAPHY; HEART FAILURE; HEART RATE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SINUS RHYTHM;

CARDIOTONIC AGENTS; DIGOXIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; HEART FAILURE, CONGESTIVE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; VENTRICULAR FUNCTION, LEFT;

EID: 0030994095     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(97)00057-0     Document Type: Article

References (46)

1. Withering W. An account of the foxglove and some of its medical uses, with practical remarks on dropsy, and other diseases. In: Willius FA, Keys TE, editors. Classics of Cardiology, Vol I. New York: Henry Schuman, Dover Publications, 1941:231-52.
2. Eichhorn EJ, Willard JE, Alvarez L, et al. Are contraction and relaxation coupled in patients with and without congestive heart failure? Circulation. 85:1992;2132-2139.
3. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 303:1980;1443-1448.
4. Gheorghiade M, St. Clair J, St. Clair C, Beller GA. Hemodynamic effects of intravenous digoxin in patients with severe heart failure initially treated with diuretics and vasodilators. J Am Coll Cardiol. 9:1987;849-857.
5. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 259:1988;539-544.
6. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med. 329:1993;1-7.
7. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, on behalf of the PROVED Investigative Group. J Am Coll Cardiol 1993;22:955-62.
8. Dibianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med. 320:1989;677-683.
9. Ferguson DW, Berg WJ, Sanders JS, Roach PJ, Kempf JS, Kienzle MG. Sympathoinhibitory responses to digitalis glycosides in heart failure patients direct evidence from sympathetic neural recordings . Circulation. 80:1989;65-77.
10. van Veldhuisen DJ, Brouwer J, Man in't Veld AJ, Dunselman PHJM, Boomsma F, Lie KI. Progression of mild untreated heart failure during six months follow-up and clinical and neurohormonal effects of ibopamine and digoxin as monotherapy. Am J Cardiol. 75:1995;796-800.
11. Gheorghiade M, Ferguson D. Digoxin a neurohormonal modulator in heart failure? Circulation. 84:1991;2181-2186.
12. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 336:1997;525-533.
13. Smith TW, Antman EM, Friedman PL, Blatt CM, Marsh JD. Digitalis glycosides: mechanisms and manifestations of toxicity. Prog Cardiovasc Dis 1984;26:413-58; 495-540.
14. Smith TW, Haber E. Digoxin intoxication the relationship of clinical presentation to serum digoxin concentration . J Clin Invest. 49:1970;2377-2386.
15. Beller GA, Smith TW, Abelmann WH, Haber E, Hood WB. Digitalis intoxication a prospective clinical study with serum level correlations . N Engl J Med. 284:1971;989-997.
16. Weissler AM, Kamen AR, Bornstein RS, Schoenfeld CD, Cohen S. The effect of deslanoside on the duration of the phases of ventricular systole in man. Am J Cardiol. 15:1965;153-161.
17. Weissler AM, Schoenfeld CD. Effect of digitalis on systolic time intervals in heart failure. Am J Med Sci. 259:1970;4-20.
18. Wilson WS, Tolbert JH, DeGuillo W. Plasma digtoxin levels and serial left ventricular ejection times after a digitalizing dose of digitoxin. Am J Cardiol. 26:1970;162-164.
19. Shapiro W, Narahara K, Taubert K. Relationship of plasma digitoxin and digoxin to cardiac response following intravenous digitalization in man. Circulation. 42:1970;1065-1072.
20. Hoeschen RJ, Cuddy TE. Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals. Am J Cardiol. 35:1975;469-472.
21. Williams JF, Klocke FJ, Braunwald E. Studies on digitalis XIII. A comparison of the effects of potassium on the inotropic and arrhythmia-producing actions of ouabain . J Clin Invest. 45:1966;346-352.
22. Klein M, Nejad NS, Lown B, Hagemeijer F, Barr I. Correlation of the electrical and mechanical changes in the dog heart during progressive digitalization. Circ Res. 29:1971;635-645.
23. Carliner NH, Gilbert CA, Pruitt AW, Goldberg LI. Effects on maintenance digoxin therapy on systolic time intervals and serum digoxin concentrations. Circulation. 50:1974;94-98.
24. Gheorghiade M, Hall VB, Jacobsen G, Alam M, Rosman H, Goldstein S. Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors. Circulation. 92:1995;1801-1807.
25. Ware JA, Snow E, Luchi JM, Luchi RJ. Effect of digoxin on ejection fraction in elderly patients with congestive heart failure. J Am Geriatr Soc. 32:1984;631-635.
26. Krum H, Bigger JT, Goldsmith RL, Packer M. Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. J Am Coll Cardiol. 25:1995;289-294.
27. Borrow KM, Green LH, Grossman W, Braunwald E. Left ventricular end-systolic stress-shortening and stress-length relations in humans normal values and sensitivity to inotropic state . Am J Cardiol. 50:1982;1301-1308.
28. Levy FL, Grayburn PA, Foulks CJ, Brickner ME, Henrich WL. Improved left ventricular contractility with cool temperature dialysis. Kidney Int. 41:1992;961-965.
29. Douglas PS, Reichek N, Plappert T, Muhammad A, St. John Sutton MG. Comparison of echocardiographic methods for assessment of left ventricular shortening and wall stress. J Am Coll Cardiol. 9:1987;945-951.
30. Albrecht P, Cohen R. Estimation of heart rate power spectrum bands from real-world data dealing with ectopic beats and noisy data . Comput Cardiol. 15:1988;311-314.
31. Rottman JN, Steinman RC, Albrecht P, Bigger JT, Rolnitzky LM, Fleiss JL. Efficient estimation of the heart period power spectrum suitable for physiologic or pharmacologic studies. Am J Cardiol. 66:1990;1522-1524.
32. Pomeranz B, Macaulay R, Caudill M, et al. Assessment of autonomic function in humans by heart rate spectral analysis. Am J Physiol. 248:1985;H151-H153.
33. Yeragani V, Srinivasan K, Venpati S, Pohl R, Balon R. Fractal dimension of heart rate time series and effective measure of autonomic function . J Appl Phys. 75:1993;2429-2438.
34. Binkley P, Cody R. Measurement of the autonomic profile in congestive heart failure by spectral analysis of heart rate variability. Heart Failure. 8:1992;154-166.
35. Akselrod S, Gordon D, Ubel F, Shannon D, Barger A, Cohen R. Power spectrum analysis of heart rate fluctuation a quantitative probe of beat-to-beat cardiovascular control . Science. 213:1981;220-222.
36. Heart rate variability standards of measurement, physiological interpretation, and clinical use . Circulation. 93:1996;1043-1065.
37. Bigger JT, Albrecht P, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Correlations among time and frequency domain measures and heart period variability two weeks after acute myocardial infarction. Am J Cardiol. 69:1992;891-898.
38. Kleiger RE, Miller JP, Bigger JT, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol. 59:1987;256-262.
39. Eichhorn EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart a new era in the treatment of heart failure . Circulation. 94:1996;2285-2296.
40. Xamoterol in severe heart failure. Lancet. 336:1990;1-6.
41. Packer M, Carver JR, Chesebro JH, et al. Effect of milrinone on mortality in severe chronic heart failure the prospective randomized milrinone survival evaluation (PROMISE) . N Engl J Med. 325:1991;1468-1475.
42. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. Lancet. 1:1988;489-493.
43. Monrad ES, Baim DS, Smith HS, Lanoue AS. Milrinone, dobutamine, and nitroprusside comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure . Circulation. 73:(Suppl III):1986;III-168-III-174.
44. Packer M, Francis GS, Abrams J, et al. Oral milrinone increases the risk of sudden death in severe chronic heart failure the PROMISE trial [abstract] . Circulation. 84:(Suppl II):1991;II-310.
45. Kernan WN, Castellsague J, Perlman GD, Ostfeld A. Incidence of hospitalization for digitalis toxicity among elderly Americans. Am J Med. 96:1994;426-431.
46. Piergies AA, Worwag EM, Atkinson AJ. A concurrent audit of high digoxin plasma levels. Clin Pharmacol Ther. 55:1994;353-358.